Sight Sciences enters its third-quarter report with a story that has changed dramatically in a matter of months. Revenue growth accelerated for three straight quarters, management raised full-year guidance twice, and the stock has climbed about 56% since the last report while the S&P 500 slipped. That combination makes the November 4 release, due after the close, less about whether the turnaround is real and more about whether the newer growth engine can keep doing the heavy lifting during a quarter management has already flagged as softer for its core glaucoma business.

The Street expects a loss of $0.12 per share on revenue of $23.4 million. That revenue figure matches the second quarter exactly and represents roughly 17.6% growth from the $19.9 million posted a year ago, a solid pace that would still mark a step down from the 20% rate that defined last quarter's inflection. The per-share loss is expected to narrow from $0.16 a year earlier but widen from the $0.08 reported last quarter. That sequential widening is not necessarily a red flag. Second-quarter results were flattered by a $1.4 million tariff refund that lifted gross margin to 91%, and management said operating spending would rise in the back half as it builds out commercial and market-access resources for its TierCare dry eye franchise, though still within a trimmed full-year expense range of $92 million to $94 million.

The consensus fits comfortably within management's framework. Full-year revenue guidance of $88 million to $92 million, combined with first-half sales of about $43 million, implies roughly $45 million to $49 million over the final two quarters. A flat third quarter leaves room for a fourth quarter anywhere inside that band. The more telling detail is the mix. Management guided interventional glaucoma to mid-single-digit growth in the third quarter, roughly flat sequentially, citing a difficult prior-year comparison and seasonal softness. With glaucoma near $20.7 million last quarter, that puts the burden of any upside squarely on interventional dry eye.

That segment is where the narrative will be confirmed or questioned. Dry eye revenue nearly doubled in each of the last two quarters, reaching $2.7 million, while ordering accounts jumped to 176 and utilization rose to about 18 smart lids per account. Yet the raised dry eye guide of $9 million to $11 million implies only about $2.5 million to $3.5 million per quarter for the rest of the year, and management said it assumes no new payer wins. A print near or above the top of that pace, along with continued growth in accounts and covered lives beyond 14.5 million, would suggest the guide is conservative and set up a third raise. A stall near last quarter's level would raise questions about whether the early surge reflected initial stocking rather than durable reordering. On the glaucoma side, the early read on Aetna's July coverage, which added about 25 million lives and completed access across all major national payers, plus any commentary on OmniUltra's launch at the AAO meeting, should matter more than the headline segment growth number.

Sentiment tells an interesting story. Bullish readings collapsed from about 34% heading into the last report to roughly 2% now, even as the stock rallied. That suggests the easy optimism has been priced in and skeptics are wary of chasing. The shares sit near $9, well above the 200-day average of about $5.95 but around 7% below the post-earnings high of $9.71, so this is a stock consolidating gains rather than pressing a breakout.

Ultimately, the report hinges on whether dry eye momentum can carry a quarter in which glaucoma was always expected to idle. If TierCare demand keeps compounding and management reaffirms or nudges up its outlook despite rising spending, the two-engine thesis holds. If dry eye flattens, a stock that has already rewarded the turnaround may find little cushion.